News headlines about Natus Medical (NASDAQ:BABY) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Natus Medical earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.3781049171239 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Natus Medical (BABY) opened at $39.10 on Tuesday. Natus Medical has a 1 year low of $31.65 and a 1 year high of $43.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36. The firm has a market cap of $1,171.40, a PE ratio of 24.26 and a beta of 0.84.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.02. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The business had revenue of $122.60 million during the quarter, compared to analyst estimates of $122.41 million. During the same period in the previous year, the business posted $0.39 EPS. The company’s quarterly revenue was up 34.9% on a year-over-year basis. equities research analysts forecast that Natus Medical will post 1.74 earnings per share for the current fiscal year.

Several research firms have recently weighed in on BABY. BidaskClub downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research report on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $46.50.

In other news, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $35.17, for a total value of $154,748.00. Following the completion of the transaction, the director now directly owns 50,850 shares of the company’s stock, valued at approximately $1,788,394.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William M. Moore sold 5,000 shares of Natus Medical stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $41.01, for a total transaction of $205,050.00. The disclosure for this sale can be found here. Insiders sold a total of 22,042 shares of company stock valued at $902,266 over the last ninety days. Company insiders own 5.50% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Stock Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related stocks with our FREE daily email newsletter.